Study S001714

Liraglutide Use in Prader-Willi Syndrome

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01542242
Study type: INTERVENTIONAL
Phase: PHASE4
Masking: NONE
Status: TERMINATED
Enrollment: 1
Start: 2012-02
Primary completion: 2013-03
Lead sponsor: Vancouver General Hospital
Conditions: Diabetes Mellitus Type 2; Prader Willi Syndrome
Interventions: DRUG:Liraglutide
Results posted: FALSE

Registered primary outcomes

Hemoglobin A1C [Change from baseline in A1C at 12 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026916	Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. Sze L, The Journal of clinical endocrinology and metabolism	2011	Other	PMID 21632815 DOI	registry reference BACKGROUND:21632815
R0027386	Liraglutide therapy in Prader-Willi syndrome. Cyganek K, Diabetic medicine : a journal of the British Diabetic Association	2011	Case report	PMID 21388446 DOI	registry reference BACKGROUND:21388446